Bourdin A, Papi AA, Corren J, et al. - Given the benefits as well as good tolerability of add‐on dupilumab 200/300 mg every 2 weeks (q2w) in phase 2b and phase 3 LIBERTY ASTHMA QUEST, as well as its general good tolerability in patients with uncontrolled, persistent (phase 2b), or moderate‐to‐severe (phase 3) asthma, researchers assessed annualized severe exacerbation rates over the treatment span, alterations from baseline in prebronchodilator forced expiratory volume in 1 second and also asthma control among patients receiving high‐dose inhaled corticosteroids (ICS) with type 2‐high asthma (subgroups with baseline blood eosinophils ≥ 150/300 cells/µL and/or fractional exhaled nitric oxide ≥ 25 ppb). As demonstrated by findings, a significant reduction in severe exacerbations as well as improvement of lung function and asthma control was conferred by treatment with dupilumab in patients with type 2‐high asthma on high‐dose ICS at baseline.